Stay Current With Our Peer-Tested Content

Welcome to the Premier Issue of Healio Rheumatology, a print publication based on the most important news as measured by the online preferences of your colleagues. In this issue, you will find the most-read content from readers of Healio.com/Rheumatology, our online news site for rheumatology. We call this unique approach to issue content selection “Peer-Tested Content” and we believe the approach will provide you the best and most valuable content in your area of expertise.

In the Trend Watch section, we feature breaking news of industry that affects your patients and practice. The Guidelines section highlights the most recent changes to published recommendations in rheumatology. In the Journals features our executive summaries of rheumatology’s most recently published peer-reviewed journal articles. Additionally, we will feature a Meeting News Coverage section to bring readers the most important highlights from rheumatology meetings and congresses held around the world.

Each issue features a Cover Story, where we look at a topic in-depth. In this premier issue, we spoke with experts Vibeke Strand, MD, MACR, FACP; Jonathan Kay, MD; and Allan Gibofsky, MD, JD, MACR, FACP, FCLM, who shared their thoughts on the topic of biosimilar therapies in rheumatology.

Leonard H. Calabrese, DO, the Chief Medical Editor of Healio Rheumatology, along with the Peer Perspective Board, will help rheumatologists keep up with advances by providing additional perspective to the current knowledge. Turn to page 8 to read Dr. Calabrese’s Editorial on the development of biosimilar therapies in rheumatology.

In this issue, we also introduce Curbside Consultation, a section where experts answer specific questions to provide their advice for better patient care. We also feature an educational activity from our Education Lab, an area of Healio.com where physicians participate in continuing medical education.

I hope Healio.com/Rheumatology becomes your daily destination for breaking news. Based on your online preferences, Healio Rheumatology aims to help you stay current on the research of your peers.

Readers are welcome to share their perspectives to the trending online content, too. Just email your comments to Rheumatology@Healio.com and you could see your perspective online and in this engaging format of print.

Please visit us online and help shape future issues, which begin regular monthly publication in March 2016. Thanks for reading.

Kristine Houck, MA, ELS
Editorial Director
Healio Rheumatology
khouck@slackinc.com

Welcome to the Premier Issue of Healio Rheumatology, a print publication based on the most important news as measured by the online preferences of your colleagues. In this issue, you will find the most-read content from readers of Healio.com/Rheumatology, our online news site for rheumatology. We call this unique approach to issue content selection “Peer-Tested Content” and we believe the approach will provide you the best and most valuable content in your area of expertise.

In the Trend Watch section, we feature breaking news of industry that affects your patients and practice. The Guidelines section highlights the most recent changes to published recommendations in rheumatology. In the Journals features our executive summaries of rheumatology’s most recently published peer-reviewed journal articles. Additionally, we will feature a Meeting News Coverage section to bring readers the most important highlights from rheumatology meetings and congresses held around the world.

Each issue features a Cover Story, where we look at a topic in-depth. In this premier issue, we spoke with experts Vibeke Strand, MD, MACR, FACP; Jonathan Kay, MD; and Allan Gibofsky, MD, JD, MACR, FACP, FCLM, who shared their thoughts on the topic of biosimilar therapies in rheumatology.

Leonard H. Calabrese, DO, the Chief Medical Editor of Healio Rheumatology, along with the Peer Perspective Board, will help rheumatologists keep up with advances by providing additional perspective to the current knowledge. Turn to page 8 to read Dr. Calabrese’s Editorial on the development of biosimilar therapies in rheumatology.

In this issue, we also introduce Curbside Consultation, a section where experts answer specific questions to provide their advice for better patient care. We also feature an educational activity from our Education Lab, an area of Healio.com where physicians participate in continuing medical education.

I hope Healio.com/Rheumatology becomes your daily destination for breaking news. Based on your online preferences, Healio Rheumatology aims to help you stay current on the research of your peers.

Readers are welcome to share their perspectives to the trending online content, too. Just email your comments to Rheumatology@Healio.com and you could see your perspective online and in this engaging format of print.

Please visit us online and help shape future issues, which begin regular monthly publication in March 2016. Thanks for reading.

Kristine Houck, MA, ELS
Editorial Director
Healio Rheumatology
khouck@slackinc.com